Vivos Therapeutics (NASDAQ:VVOS) specializes in developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The company is known for its proprietary Vivos Method, a non-invasive, multifaceted approach to rectify the underlying causes of OSA. By focusing on the dental and orthodontic space, Vivos Therapeutics aims to bring about significant improvements in overall health outcomes for patients dealing with sleep apnea and related conditions. Central to its objectives is the ambition to expand the accessibility of its treatment solutions across diverse patient demographics, striving to alleviate the burdens of sleep-disordered breathing on a global scale.